ReviewOncotarget2023
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
Review in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Essential Oils as a Source of Anticancer Molecules: Critical Assessment of Current Evidence and Methodological Limitations-A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Hydrazones as Potential Antimelanoma Prototypes: A Systematic and Patent Review.Anti-cancer agents in medicinal chemistry · 2026Pooled it
- Carotenoid-Rich Pigment Extract From Micrococcus terreus SK34 Induces Apoptosis in SH-SY5Y Neuroblastoma Cells: Integrated Metabolomic, Molecular Docking, and Experimental Validation.MicrobiologyOpen · 2026Article
- Twenty-Five Years of the Environmental Stress Response and the Enduring Power of Yeast in Stress Biology.Yeast (Chichester, England) · 2026Review
- Degraded sulfated galactan derived fromMolecular medicine reports · 2026Article
- Article
- Chalcones as multitarget modulators in non-small cell lung cancer: mechanistic insights and therapeutic perspectives.Archives of toxicology · 2026Review
- Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure.Journal of translational medicine · 2026Review
- D-salicin induces oxidative stress-mediated ERK1/2 suppression and apoptosis in endometrial cancer cells.Oncology letters · 2026Article
- Instant Cascara Beverages with Inulin-Type Carriers: Production Yield, In Vitro Biological Activity and Receptor-Level Responses.Nutrients · 2026Article
- CDK9 inhibition triggers MT2A-dependent apoptosis in HCC cells.Genes & genomics · 2026Article
- In Vitro Evidence for the Dual Antioxidant and Anti-Inflammatory Roles ofMolecules (Basel, Switzerland) · 2026Article
- New predicted dual CDK-2/CDK-1 inhibitors from Aspergillus unguis isolate SP51-EGY with relative selectivity for colorectal cancer cells: a computational and experimental approach.Scientific reports · 2026Article
- Niacin Protects iPSC-Derived Neurons from Chemotherapy-Induced Toxicity.Neurotoxicity research · 2026Article
- BRCA1 and BRCA2 gene expression: p53- and cell cycle-dependent repression requires RB and DREAM.Cell death and differentiation · 2026Article
- Article
- A novel pyrrolidine-chalcone derivative exhibits synergistic anti-cervical cancer activity by dual-targeting MDM2-p53 axis and ferroptosis pathway.Frontiers in pharmacology · 2026Article
- The unsolvable problem of traumatic brain injury (or how to stop wasting money in fruitless research).Surgical neurology international · 2026Review
- Review
- In vitro analysis of the anticancer and antimicrobial potentials and phytochemical profiles of leaf extracts from five Vachellia species.Current research in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. Paradoxically, cancer resistance to certain therapies can be exploited for protection of normal cells, simultaneously enabling the selective killing of resistant cancer cells by using antagonistic drug combinations, which include cytotoxic and protective drugs. Depending on the mechanisms of drug-resistance in cancer cells, the protection of normal cells can be achieved with inhibitors of CDK4/6, caspases, Mdm2, mTOR, and mitogenic kinases. When normal cells are protected, the selectivity and potency of multi-drug combinations can be further enhanced by adding synergistic drugs, in theory, eliminating the deadliest cancer clones with minimal side effects. I also discuss how the recent success of Trilaciclib may foster similar approaches into clinical practice, how to mitigate systemic side effects of chemotherapy in patients with brain tumors and how to ensure that protective drugs would only protect normal cells (not cancer cells) in a particular patient.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.